5 May 2020 - Pfizer and BioNTech ramping up manufacturing capabilities to further increase production capacity in 2020/2021.
Pfizer and BioNTech announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19.
The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.